0001104659-19-033124.txt : 20190531 0001104659-19-033124.hdr.sgml : 20190531 20190531160903 ACCESSION NUMBER: 0001104659-19-033124 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190529 ITEM INFORMATION: Other Events FILED AS OF DATE: 20190531 DATE AS OF CHANGE: 20190531 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BRUKER CORP CENTRAL INDEX KEY: 0001109354 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] IRS NUMBER: 043110160 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-30833 FILM NUMBER: 19870517 BUSINESS ADDRESS: STREET 1: 40 MANNING RD CITY: BILLERICA STATE: MA ZIP: 01821 BUSINESS PHONE: 978663-3660 MAIL ADDRESS: STREET 1: 40 MANNING RD CITY: BILLERICA STATE: MA ZIP: 01821 FORMER COMPANY: FORMER CONFORMED NAME: BRUKER BIOSCIENCES CORP DATE OF NAME CHANGE: 20030721 FORMER COMPANY: FORMER CONFORMED NAME: BRUKER DALTONICS INC DATE OF NAME CHANGE: 20000315 8-K 1 a19-10946_18k.htm 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d)

of the Securities Exchange Act of 1934

 

 

Date of Report (Date of earliest event reported): May 29, 2019

 

BRUKER CORPORATION

(Exact name of registrant as specified in its charter)

 

Delaware

 

000-30833

 

04-3110160

(State or other jurisdiction

 

(Commission

 

(IRS Employer

of incorporation)

 

File Number)

 

Identification No.)

 

40 Manning Road
Billerica, MA 01821
(Address of principal executive offices)(Zip Code)

 

Registrant’s telephone number, including area code: (978) 663-3660

 

 

Check the appropriate box if the Form 8-K filing is intended to simultaneously satisfy the reporting obligation of the registrant under any of the following provisions:

 

o     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o     Soliciting material pursuant to Rule 14a-12 of the Exchange Act (17 CFR 240.14a-12)

o     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class

 

Trading Symbol(s)

 

Name of Each Exchange on Which Registered

Common Stock, $0.01 par value per share

 

BRKR

 

The Nasdaq Global Select Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

 

Emerging growth company  o

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

 

 

 

 

Section 8 — Other Events

 

Item 8.01.  Other Events.

 

Bruker Corporation (“Bruker” or the “Company”) has been advised that Robyn L. Laukien, the former spouse of Bruker’s President and CEO Frank H. Laukien, is in the process of selling up to 800,000 of her shares of Bruker common stock in open market transactions as part of her plans for estate planning and portfolio diversification. Robyn Laukien has owned all economic rights over these shares for over ten years, and has sole investment authority over such shares.

 

Frank Laukien has held a voting proxy over Robyn Laukien’s shares of Bruker common stock for over ten years, which continues to be in existence for the remaining over 1.04 million shares of Bruker common stock that Robyn Laukien is expected to continue to own.  Frank Laukien is not selling any Bruker shares that are directly owned by him and is not a participant in these transactions.

 

The Company has been informed that Robyn Laukien’s sale transactions commenced on May 29, 2019. As a result of the voting proxy granted to Frank Laukien, sale transactions effected by Robyn Laukien will be reported on Form 4 reports filed by Frank Laukien with the U.S. Securities and Exchange Commission. It is expected that Robyn Laukien’s remaining shares of Bruker common stock will continue to be reported as indirect holdings on Frank Laukien’s Form 4 reports during the remaining term of the voting proxy.

 

2

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

BRUKER CORPORATION
(Registrant)

 

 

 Date: May 31, 2019

By:

/s/GERALD N. HERMAN

 

 

Gerald N. Herman

 

 

Chief Financial Officer

 

3